Accelerating Research to Save Lives
The Prostate Cancer Foundation (PCF) funds the world’s most promising research on the biology and treatment of prostate cancer, accelerating those discoveries into therapies and strategies to improve the quality of life and overall survival of patients. PCF is committed to bringing together patients, researchers, caregivers, and clinicians into a singular community focused on reducing death and suffering from this disease.
30 Years of Impact
In 1993, prostate cancer research was underfunded, awareness was low, and collaboration among researchers was limited. Determined to change this, Milken founded the Prostate Cancer Foundation (formerly known as CaP CURE) with a mission to accelerate research, simplify grant processes, and advance understanding of prostate cancer.
PCF has contributed to a 20 fold increase in government funding.
1.4 Million prostate cancer deaths have been averted.
Since PCF’s founding, the death rate has been cut in half.
Funding for more than 2,250 research programs at over 245 cancer centers.
Support of 14 new prostate cancer therapies.
Established 21 PCF-VA precision oncology Centers of Excellence.
A Catalyst for Change
The Prostate Cancer Foundation (PCF), originally founded as CaP CURE, set out to transform prostate cancer research and treatment. At the time, the PSA screening test was new, there were only three drugs for advanced disease, and the outlook for metastatic prostate cancer was bleak. PCF pioneered a new funding model, becoming a catalyst for change.
PCF’s Approach
Today, PCF fosters unity and progress through scientific, human, and social investments, leading to more effective treatment options for patients, and hope for a future beyond their diagnosis.
Invest in Science
Rapid, efficient funding of ambitious research projects with the greatest potential to discover cures